Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flaviolin is a natural 1,4-naphthoquinone derivative, chemically identified as 2,5,7-trihydroxy-1,4-naphthoquinone, produced by various microorganisms including *Aspergillus* species and *Streptomyces griseus*. It is a polyketide synthesized by type III polyketide synthases (such as RppA or ThnA) through the spontaneous oxidation of 1,3,6,8-tetrahydroxynaphthalene (THN). In the field of synthetic biology and metabolic engineering, flaviolin is widely employed as a colorimetric reporter to monitor malonyl-CoA levels due to its characteristic red pigmentation. Therapeutically, it has been investigated for its antineoplastic activity, particularly against multiple myeloma, where it induces S-phase cell-cycle arrest and triggers apoptosis through the mitochondrial pathway and caspase-9 activation. It also serves as a biosynthetic precursor or shunt product for other complex natural products, including meroterpenoids and melanins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flaviolin.